title: The soluble metal-binding domain of the copper transporter ATP7B binds and detoxifies cisplatin.
abstract: Wilson disease ATPase (ATP7B) has been implicated in the resistance of cancer cells to cisplatin. Using a simple in vivo assay in bacterial culture, in the present study we demonstrate that ATP7B can confer resistance to cisplatin by sequestering the drug in its N-terminal metal-binding domain without active drug extrusion from the cell. Expression of a protein fragment containing four N-terminal MBRs (metal-binding repeats) of ATP7B (MBR1-4) protects cells from the toxic effects of cisplatin. One MBR1-4 molecule binds up to three cisplatin molecules at the copper-binding sites in the MBRs. The findings of the present study suggest that suppressing enzymatic activity of ATP7B may not be an effective way of combating cisplatin resistance. Rather, the efforts should be directed at preventing cisplatin binding to the protein.
authors.affiliation: Department of Biochemistry, University of Saskatchewan, Saskatoon, SK, Canada.
authors.forename: Nataliya V
authors.initials: NV
authors.lastname: Dolgova
authors.forename: Doug
authors.initials: D
authors.lastname: Olson
authors.forename: Svetlana
authors.initials: S
authors.lastname: Lutsenko
authors.forename: Oleg Y
authors.initials: OY
authors.lastname: Dmitriev
mesh_terms: D000251:Adenosine Triphosphatases / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D001665:Binding Sites; D027682:Cation Transport Proteins / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D002945:Cisplatin / Q000378:metabolism* / Q000494:pharmacology; D000073840:Copper-Transporting ATPases; D004926:Escherichia coli / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D006527:Hepatolenticular Degeneration / Q000378:metabolism; D008857:Microscopy, Interference; D011485:Protein Binding; D017434:Protein Structure, Tertiary
chemical_list: D027682:Cation Transport Proteins; D000251:Adenosine Triphosphatases; D000073840:Copper-Transporting ATPases; D002945:Cisplatin